C71T
CANCELLED SECTION 71
03/06/2026
Back to search
Official data from USPTO
FLEXISEQ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
FLEXISEQ
ST13
US500000079115213Class
1, 5, 10
Filing
79115213
Registration
4437885
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
03/31/2026
Trademark type
Word
Nice classes
1, 5, 10
Filing date
12/12/2011
Registration date
11/26/2013
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/06/2026
Last transaction
03/31/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Berkshire, GB
Examiner
BUONGIORNO, CHRISTOPHER L
Law office
L20
Holders and representatives
Holders
Pro Bono Bio Entrepreneur Limited
Pro Bono Bio Entrepreneur Limited
Representatives
Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Surfactants and lipids for use in the manufacture of personal care productschemical products for in vitro and in vivo use in research and development
Class 5
Pharmaceutical preparations and substances for the treatment of pain and inflammation; veterinary and sanitary preparations and substances for the treatment of pain and inflammation; chemical preparations for pharmaceutical purposesfor the treatment of pain and inflammation; diagnostic preparations and substances for medical purposes for in vivo use; pharmaceuticals for treating osteoarthritisoncologycardiovascular diseaserespiratory diseaseinflammationinfectiongastrointestinal diseases and central nervous system diseases; diagnostic preparation for medical and veterinary use; topical and parenteral preparations of vesiclesliquids or gels for the treatment of pain and inflammation; chemical preparations for the treatment of pain and inflammation in the form of vesicles for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammation; dispersions and dry preparations of liposomal active substance carriers for use as a pharmaceuticalcosmetic substance carrierin the nature of a liquidgelcreamlotion or lipid; cosmeceutical preparations in the nature of medicated cosmetics; local anesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; topical and parenteral lipids for use in the treatment of pain and inflammation; medicated creamsmedicated dispersionsmedicated lotionsmedicated ointmentsmedicated gelsmedicated solutionsmedicated spraysmedicated lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain and inflammation; surfactants for medical use in the treatment of or prevention of cancerinfectious diseasefungal diseasesdisease caused by parasiteseye diseasediseases of the central and peripheral nervous systemscardiovascular diseasediseases affecting the immune systeminflammatory diseasessingle gene disordersdiseases of the mouthteethskinhair and earbone and blood diseases and reproductive system disordersthe treatment of inflammationasthmaatopic eczemadishydrotic hand eczemaplaque type psoriasisseborrhoeic eczemaacne vulgarisbronchospasmatherothrombotic cardiovascular disordersvenous thrombotic disorderspaindysmenorrheahypercholesterolemiahypertriglyceridemiafatty acid metabolismmetal or other toxicityAlzheimer's diseasegoutmacular degenerationage-related macular degenerationfungal infection and disorders related to fatty acid deficiencies
Class 10
Medical devices in the nature of a carrier with nanostructures which cross through the skin for the treatment of pain and inflammation associated with osteoarthritis; molecular filtering devices for medical usea liquid or gel as a drug delivery device which filters through the skin and has a physical therapeutic effect at the point of complaint; medicalveterinary and surgical devicesa medical device which acts as a drug delivery system in the nature of non-pharmaceutical nanostructures that migrate through the skin and have a physical therapeutic effect at the point of complaint ; inhalers for medical purposes sold empty; injection devicesmedical syringes and medical fluid injectors; medical instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances
Publications
History of USPTO decisions and trademark events.
50 publications found
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
11/26/2022
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/30/2021
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
11/07/2020
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
10/01/2020
INPC
INVALIDATION PROCESSED
10/01/2020
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
09/08/2020
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
01/08/2020
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
01/08/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/03/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/09/2019
ES75
TEAS SECTION 71 & 15 RECEIVED
11/04/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/09/2019
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
11/26/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/14/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/14/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/13/2014
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/27/2014
FIMP
FINAL DISPOSITION PROCESSED
02/27/2014
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/26/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
11/26/2013
GPNX
NOTIFICATION PROCESSED BY IB
09/15/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/10/2013
PUBO
PUBLISHED FOR OPPOSITION
09/10/2013
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/28/2013
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/28/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/21/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/07/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/15/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/15/2013
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/15/2013
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/11/2013
GNFR
FINAL REFUSAL E-MAILED
03/11/2013
CNFR
FINAL REFUSAL WRITTEN
03/11/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/14/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/14/2013
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/08/2013
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/08/2013
ALIE
ASSIGNED TO LIE
02/08/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/08/2013
RFNT
REFUSAL PROCESSED BY IB
09/01/2012
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/15/2012
RFRR
REFUSAL PROCESSED BY MPU
08/15/2012
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/14/2012
MAFR
APPLICATION FILING RECEIPT MAILED
08/14/2012
CNRT
NON-FINAL ACTION WRITTEN
08/13/2012
DOCK
ASSIGNED TO EXAMINER
08/08/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/08/2012
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/02/2012
Continuous trademark protection
Get notified about every new filing that threatens FLEXISEQ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.